ARTICLE | Clinical News
Emricasan: Ph IIb started
November 18, 2016 6:21 PM UTC
Conatus began the double-blind, placebo-controlled, international Phase IIb ENCORE-PH trial to evaluate 5, 25 and 50 mg oral emricasan twice daily for 24 weeks in about 240 patients with compensated o...
BCIQ Company Profiles
BCIQ Target Profiles